6th Annual Viral Hepatitis Drug Discovery & Development

Venue: Hyatt Regency Princeton

Location: Princetom, New Jersey, United States

Event Date/Time: Jan 12, 2005
Report as Spam

Description

Now in its 6th successful year, Strategic Research Institute’s Annual Antiviral Drug Discovery & Development Summit has established itself as the must-attend industrial science and networking event by focusing in the areas of HIV, hepatitis, herpes viruses, respiratory, and other related antiviral diseases.

In 2005, Strategic Research Institute has organized a more scientific and medical specialist agenda by focusing on an area of growing and commercial endeavor, Hepatitis B and Hepatitis C. Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated. HBV affects over 2 billion people in the world today while HCV affects approximately 4 million people each year. With this in mind, the Antiviral meeting has transformed from a broad to a more focused meeting on Viral Hepatitis in Drug Discovery & Development Summit.

You will have plenty of opportunity to participate in the excellent networking and business development opportunities at the meeting by interacting with the leading scientists and decision-makers from the pharmaceutical/biotech industry, public health, and academic communities working in the area of viral hepatitis of North America and internationally.

SECTIONS INCLUDE:

Interferon Mechanisms
HCV Protease Inhibitors
HCV Polymerase Inhibitors
Other HCV Targets/Agents
Novel Advances in HBV Therapeutics
KEYNOTE: Challenges for New Hepatitis B and C Therapies

Ira M. Jacobson, MD
Chief of the Division of Gastroenterology and Hepatology
Vincent Astor Distinguished Professor of Clinical Medicine
THE JOAN SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
FEATURED PRESENTATIONS:

Hepatitis C: Virology, Biology, and Therapeutic/Preventative Targets

Michael Houghton, Ph.D.
Vice President of HCV Vaccines Research
CHIRON CORPORATION
Limiting Cellular Antiviral Defenses through Proteolytic Cleavage of Cellular Substrates by the Hepatitis C Virus NS3/4A Protease

Kui Li, M.D., Ph.D.
Assistant Professor, Department of Microbiology and Immunology
UNIVERSITY OF TEXAS MEDICAL BRANCH
RNAi-based Therapies for Viral Hepatitis

Mark A. Kay, MD, PhD
Professor, Departments of Pediatrics and Genetics
Director, Program in Human Gene Therapy
STANFORD UNIVERSITY SCHOOL OF MEDICINE
PARTICIPATING COMPANIES:

Boehringer-Ingelheim
Bristol-Myers Squibb
Chiron Corporation
Gilead Sciences
GlaxoSmithkline
Idenix Pharmaceuticals
Innogenetics
Medivir UK
Merck Research Laboratories
Nucleonics
Pfizer Groton R&D – La Jolla
Rigel, Inc.
Roche
Schering-Plough Corporation
Sirna Therapeutics
Stanford University School of Medicine
St. Luke’s Texas Liver Institute
University of Texas Medical Branch
Valeant Pharmaceuticals
Vertex Pharmaceuticals
Weill Medical College of Cornell University
For more information about the conference or speaking opportunities, please contact the organizer Glenn Pascual at gpascual@srinstitute.com or call 212.967.0095, ext. 245

Venue

102 Carnegie Center
Princetom
New Jersey
United States
MORE INFO ON THIS VENUE